Tag: biomarker

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Advanced In Vivo Efficacy Models for Preclinical Success, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how in vivo PK/PD and efficacy models drive progress in oncology, immunology and fibrosis, with real-world case studies showcasing...

Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting

The Biomarkers Market is anticipated to expand at a rapid pace due to the increasing demand for personalized medicine, rising prevalence of chronic and...

JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio’s DEX-G2 Blood Test For Early Detection of Gastric Cancer

SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance...

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction

www.freyapharmasolutions.com

NeuroSense Provides Business Update and Progress for the First Half of 2025

CAMBRIDGE, Mass., July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided...

NiaHealth Taps ex-HelloFresh Exec as First Chief Marketing Officer and Announces Product Expansion as Company Enters Hyper-Growth Phase

Award-winning marketing leader Candy Lee joins NiaHealth amidst accelerating demand, expanded clinical care, and the announcement of significant product expansion as Canada's most comprehensive...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of...

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsBiomarker

Vincere Portfolios Reports Six Years of Audited Algorithm Performance as Demand Grows for Systematic Investing Solutions

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

In HelloNation, HVAC Expert Anthony Lane Explains What to Do When an Air Conditioner Stops Working

Tag: biomarker

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

Advanced In Vivo Efficacy Models for Preclinical Success, Upcoming Webinar Hosted by Xtalks

Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting

JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio’s DEX-G2 Blood Test For Early Detection of Gastric Cancer

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction

NeuroSense Provides Business Update and Progress for the First Half of 2025

NiaHealth Taps ex-HelloFresh Exec as First Chief Marketing Officer and Announces Product Expansion as Company Enters Hyper-Growth Phase

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us